Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2017 1
2018 1
2019 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G. Martin P, et al. Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26. Gut. 2015. PMID: 25429051 Free PMC article.
Following a single administration in mice, TG1050 induced robust, multispecific and long-lasting HBV-specific T cells detectable up to 1 year post-injection. ...These results warrant clinical evaluation of TG1050 in the treatment of CHB....
Following a single administration in mice, TG1050 induced robust, multispecific and long-lasting HBV-specific T cells detectable up t …
A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.
Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. Kratzer R, et al. Hum Vaccin Immunother. 2018 Jun 3;14(6):1417-1422. doi: 10.1080/21645515.2018.1433970. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29388874 Free PMC article.
HBV-DNA (viremia) and HBsAg levels, were 52% and 51% in TG1050 treated mice, compared with 8% and 22%, respectively, in untreated mice. No significant impact of HBsAg level at baseline on response to TG1050 treatment was found. TG1050-treated mice displayed a …
HBV-DNA (viremia) and HBsAg levels, were 52% and 51% in TG1050 treated mice, compared with 8% and 22%, respectively, in untreated mic …
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G. Zoulim F, et al. Hum Vaccin Immunother. 2020;16(2):388-399. doi: 10.1080/21645515.2019.1651141. Epub 2019 Oct 4. Hum Vaccin Immunother. 2020. PMID: 31373537 Free PMC article. Clinical Trial.
All doses were well tolerated in both cohorts, without severe adverse event. TG1050 was capable to induce IFN-gamma producing T-cells targeting 1 to 3 encoded antigens, in particular at the 10(10)vp dose. Overall, minor decreases of HBsAg were observed while a number of va …
All doses were well tolerated in both cohorts, without severe adverse event. TG1050 was capable to induce IFN-gamma producing T-cells …
Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
Huang D, Sansas B, Jiang JH, Gong QM, Jin GD, Calais V, Yu DM, Zhu MY, Wei D, Zhang DH, Inchauspé G, Zhang XX, Zhu R. Huang D, et al. J Viral Hepat. 2017 Nov;24 Suppl 1:66-74. doi: 10.1111/jvh.12791. J Viral Hepat. 2017. PMID: 29082648
To support the clinical development of TG1050 in China, specific immunity to the fusion antigens of TG1050 was assessed in Chinese patients. ...These observations support the extended application and associated immune monitoring of TG1050 in China....
To support the clinical development of TG1050 in China, specific immunity to the fusion antigens of TG1050 was assessed in Chi …
Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?
Yang HC, Kao JH. Yang HC, et al. Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):129-31. doi: 10.1038/nrgastro.2015.8. Epub 2015 Jan 27. Nat Rev Gastroenterol Hepatol. 2015. PMID: 25623202
Martin et al. developed a novel adenovirus-based therapeutic vaccine TG1050 and demonstrated its induction of long-lasting antiviral CD8+ T-cell immunity in mouse models of HBV persistence....
Martin et al. developed a novel adenovirus-based therapeutic vaccine TG1050 and demonstrated its induction of long-lasting antiviral …
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML. Godon O, et al. Vaccine. 2015 Aug 26;33(36):4548-53. doi: 10.1016/j.vaccine.2015.07.020. Epub 2015 Jul 23. Vaccine. 2015. PMID: 26209840
Using peripheral blood mononuclear cells from 23 patients chronically infected by five distinct genotypes (gt A, B, C, D and E) and various sets of peptides encompassing conserved versus divergent regions of HBV core we have measured ability of TG1050 genotype D core-deriv …
Using peripheral blood mononuclear cells from 23 patients chronically infected by five distinct genotypes (gt A, B, C, D and E) and various …